ANGLE PLC

Share Issue/Capital Change • Mar 4, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 4613G

Angle PLC

04 March 2015

For immediate release	4 March 2015

ANGLE plc

("ANGLE" or "the Company")

OFFER TO SHAREHOLDERS TO RAISE UP TO £1.5 MILLION

On 16 February 2015, ANGLE plc (AIM: AGL and OTCQX: ANPCY), the specialist medtech company, announced an issue of equity to raise £7.3 million (before expenses) by way of a Placing and Subscription.  In conjunction with the Placing and Subscription, the Board also announced details of an Offer to Qualifying Participants to raise up to an additional £1.5 million (before expenses) through the issue of up to 2,307,692 New Ordinary Shares at an Issue Price of 65 pence per Ordinary Share.

The Company is pleased to announce that the Offer, which closed at 11.00 a.m. on 2 March 2015, was more than four times oversubscribed.  The Offer raised the Offer Maximum of £1.5 million and, accordingly, 2,307,692 New Ordinary Shares have been issued. It is expected that Qualifying Participants that applied for the Offer will each receive approximately 21.75% of their applications.

Application has been made for 2,307,692 New Ordinary Shares to be admitted to trading on AIM.  It is expected that admission to AIM will become effective on 10 March 2015.

Further details of the Placing, Subscription and Offer were set out in the announcement published by the Company on 16 February 2015.

Unless otherwise defined, capitalised terms shall have the same meaning as defined in the circular posted to Shareholders on 16 February 2015 (the "Circular"), which is available to view on the Company's website at www.angleplc.com.

ANGLE's Founder and Chief Executive, Andrew Newland, commented:

"We are delighted to have received such a strong level of support from our retail shareholders with the Offer more than four times over-subscribed. In total we have raised £8.2 million net of expenses in our Placing, Subscription and Offer, which puts ANGLE in a strong position to progress its first clinical application in ovarian cancer."

For further information:

ANGLE plc	01483 685830
Andrew Newland, Chief Executive Ian Griffiths, Finance Director
Cenkos Securities Stephen Keys, Dr Christopher Golden (Nominated adviser) Russell Kerr, Oliver Baxendale (Sales)	020 7397 8900
Buchanan Mark Court, Sophie Cowles, Jane Glover	020 7466 5000

This information is provided by RNS

The company news service from the London Stock Exchange

END

IOEJJMJTMBTMTJA